Greg Perry is the Chief Financial Officer of Finch Therapeutics, a company focused on translating insights from real-world clinical evidence into next-generation microbiome therapies. Greg has over 20 years of corporate finance experience in the biopharmaceutical industry, including leading several strategic transactions and raising more than $1 billion of capital, including an IPO. Prior to joining Finch, Greg held various senior financial leadership roles at several biotech companies including Novelion Therapeutics, Eleven Biotherapeutics, ImmunoGen, Domantis, and Transkaryotic Therapies. He currently serves on the Board of Directors of Merus Therapeutics and Kala Pharmaceuticals. He transitioned to the biotech industry after beginning his career at General Electric, where he served in increasingly senior financial roles over fourteen years. He earned a B.A. in Economics and Political Science from Amherst College.